Stocks and InvestingStocks and Investing
Wed, January 4, 2023
Tue, January 3, 2023
Fri, December 30, 2022
Thu, December 29, 2022
Wed, December 28, 2022
Tue, December 27, 2022
Fri, December 23, 2022
Thu, December 22, 2022
Wed, December 21, 2022

David Westenberg Upgraded (ADPT) to Buy and Increased Target to $14 on, Dec 21st, 2022


Published on 2024-10-28 00:40:59 - WOPRAI, David Westenberg
  Print publication without navigation


David Westenberg of Piper Sandler, Upgraded "Adaptive Biotechnologies Corporation" (ADPT) to Buy and Increased Target from $7.5 to $14 on, Dec 21st, 2022.

David has made no other calls on ADPT in the last 4 months.



There are 2 other peers that have a rating on ADPT. Out of the 2 peers that are also analyzing ADPT, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Tejas Savant of "Morgan Stanley" Maintained at Hold with Decreased Target to $16 on, Monday, November 7th, 2022


This is the rating of the analyst that currently disagrees with David


  • Dan Leonard of "Credit Suisse" Initiated at Sell and Held Target at $8 on, Thursday, August 25th, 2022